New Treatments Target HER2 in Gastric Cancers : Oncology Times

An abstract is unavailable.

Source: journals.lww.com

Categories: Oncologists1, General Medicine News

Tags: gastriccancer

Tweets with this article

Oncology Times

“Among U.S. patients, #GastricCancer is often diagnosed at an advanced stage where prognosis is poor,” Cartwright said. The 5-year survival rate for gastric cancer across all stages is approximately 36.4% in the U.S. https://t.co/2gkQ0jctZl https://t.co/xgQc2uearv

NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers

NRG1 fusion positivity has gained interest as a treatment target in lung and pancreatic cancer, leading to the FDA approval of zenocutuzumab in December 2024.

OncLive.com January 4, 2025

Is Neurotechnology Developing Faster Than Its Ethical and… : Neurology Today

An abstract is unavailable.

Neurology Today January 4, 2025

Novel CAR T-Cell Therapy Trial Advances to Third Cohort in Ovarian Cancer

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its third cohort.

Targeted Oncology January 4, 2025

Fertility Counseling and Preservation in Patients With NHL | Blood Cancers Today

Researchers say barriers such as time constraints and financial limitations complicate fertility counseling and preservation for patients with lymphoma.

Blood Cancers Today January 4, 2025

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care.

OncLive.com January 4, 2025